Should You Buy Acumen Pharmaceuticals Inc (ABOS) Stock on Friday?

The market has been down on Acumen Pharmaceuticals Inc (ABOS) stock recently. ABOS gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Acumen Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ABOS!

See Full ABOS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ABOS Stock Today?

Acumen Pharmaceuticals Inc (ABOS) stock is trading at $2.23 as of 1:02 PM on Friday, Nov 3, a rise of $0.27, or 13.78% from the previous closing price of $1.96. The stock has traded between $2.00 and $2.30 so far today. Volume today is 551,417 compared to average volume of 496,025. To see InvestorsObserver's Sentiment Score for Acumen Pharmaceuticals Inc click here.

More About Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Click Here to get the full Stock Report for Acumen Pharmaceuticals Inc stock.